Table 1 The efficacy of indications in detecting chromosomal abnormality
From: Cell-free fetal DNA testing and its correlation with prenatal indications
Clinical indications | Characteristic | Population with high risk | T21 | T18 | T13 | SCAs | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total(%) | Maternal age (years) | GA at NIPT (wks) | P (TP) | PPV | P (TP) | PPV | P (TP) | PPV | P (TP) | PPV | P (TP) | PPV | |
AMA (≥35 years) | 3295 (23.02) | 37.39 ± 2.37 | 16.54 ± 2.58 | 63 (38) | 60.32% | 23 (21) | 91.30% | 8 (6) | 75.00% | 6 (2) | 33.3% | 15 (9) | 60.00% |
aMSS | 7608 (53.14) | 28.06 ± 3.52 | 17.40 ± 2.83 | 24 (11) | 45.83% | 5 (5) | 100.00% | 2 (1) | 50.00% | 1 (0) | 0.00% | 8 (5) | 62.50% |
abnormally thickened NT | 120 (0.84) | 27.58 ± 3.54 | 15.32 ± 2.17 | 5 (3) | 60.00% | 1 (1) | 100.00% | 2 (2) | 100.00% | 0 (0) | NA | 1 (0) | 0.00% |
aUS | 112 (0.78) | 27.69 ± 3.22 | 22.69 ± 3.04 | 3 (1) | 33.33% | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA | 2 (1) | 50.00% |
Twin /IVF-ET pregnancy | 429 (3.00) | 28.81 ± 3.27 | 15.26 ± 2.05 | 6 (5) | 83.33% | 3 (3) | 100.00% | 0 (0) | NA | 0 (0) | NA | 3 (2) | 66.67% |
Miss other screening opportunities | 5 (0.03) | 25.80 ± 2.99 | 25.40 ± 0.49 | 0 (0) | 0.00% | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA |
Voluntary Testing | 2524 (17.63) | 27.59 ± 3.68 | 16.03 ± 2.23 | 88 (42) | 47.73% | 17 (15) | 88.24% | 4 (2) | 50.00% | 9 (4) | 44.44% | 34 (21) | 61.76% |
Interventional surgery contraindication | 14 (0.10) | 27.64 ± 2.12 | 16.29 ± 1.39 | 0 (0) | 0.00% | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA |
Other risk factors | 209 (1.46) | 28.44 ± 3.41 | 15.35 ± 2.35 | 0 (0) | 0.00% | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA | 0 (0) | NA |
Total | 14,316 | 189 (100) | 59.79% | 49 (45) | 91.84% | 16 (11) | 68.75% | 16 (6) | 37.5% | 63 (38) | 60.32% | ||